Trial
NCT03572634
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Sumitomo Pharma America, Inc.
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
TP-0903
Why stopped
Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to include this study of TP-0903.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-09